MedPath

Performance and Safety of thermotherapy with nanoparticles (NanoTherm® Therapy System) as an adjuvant therapy to the Standard of Care treatment of patients with recurrent glioblastoma

Conditions
C71.9
Brain, unspecified
Registration Number
DRKS00023339
Lead Sponsor
MagForce AG
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Recruiting stopped after recruiting started
Sex
All
Target Recruitment
5
Inclusion Criteria

Male and female patients with recurrent glioblastoma (first or repeated recurrence)
Age 18-75 Years
Informed Consent in writing
Karnofsky Index = 60
Life expectancy > 6 months
Failed standard therapy (Stupp regiment, TTF)
Stable corticoid requirements = 2mg dexamethasone / d
Known Molecular differentiation (MGMT promoter methylation, IDH mutation status, 1p/19q deletion status)
Cardiopulmonary compliance (heat and lying flat in the field generator for approx. 60 minutes must be tolerated
Psychological resilience

Exclusion Criteria

Patients older than 75years
Pregnant or breast-feeding women
> 3 multiple glioblastoma lesions
Speech or motor brain functions in/at resection area
Subependymal contrast enhancement in adjacent ventricles
Simultaneous therapy with immunomodulators
Metallic implants =40cm from the planned alternating field, e.g. dental seals, cervical spine implants, implant remnants from previous craniotomies, orthopedic trauma osteosynthesis material, port systems with a metallic base
Electronic implants, e.g. cardiac pacemakers or defibrillators, cochlear implants, DBS
Allergy/hypersensitivity to aminosilanes, iron oxide, acetic acid
Planned or current therapy with Optune®TTF
Uncontrolled claustrophobia
Pain caused by arthrosis and degenerative spinal disorders, which may not be controlled

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Safety: AE/SAE frequency (ask throughout the study)<br>Efficacy: OS-2 (survival after diagnosis of recurrence) ; evaluation at the end of the study.
Secondary Outcome Measures
NameTimeMethod
Quality of life after treatment with NanoTherm® Therapy System
© Copyright 2025. All Rights Reserved by MedPath